Skip to content
DataLookout
Menu

TEDOVANCT04713514

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 17 versions: 16 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Study completion date changed from estimate of Dec 31, 2026 to Nov 9, 2026
  2. Notable Eligibility criteria expanded, about 41 words Show 9 more changesShow less
    • Study completion pushed from Dec 2025 to Dec 31, 2026
    • Enrollment target: estimated 180 to confirmed 185
    • Study sites: 40 to 41
    • Primary completion date changed from estimate of Dec 2025 to Dec 15, 2025
    • Interventions: OSE2101 (Drug), Pembrolizumab 25 MG/ML [Keytruda] (Drug) to OSE2101 (Drug), Pembrolizumab 25 MG/ML [Keytruda] (Drug)
    • Secondary endpoints: details revised at 4 of 5 entries
    • Collaborators: details revised at 1 of 2 entries
    • Publications: details revised at 1 of 1 entry
    • Study description expanded, about 3 words
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 43 to 40
    v15
  4. Minor Study sites: 42 to 43v14
  5. Minor Site contacts updated at 1 of 42 sitesv13
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Eligibility criteria shortened, about 19 words
    • Study sites: 38 to 42
    • Primary and study completion dates: Jun 2025 to Dec 2025
    v12
  2. Minor Study sites: 29 to 38v10
  3. Minor Site details revised at 5 of 29 sitesv9
  4. Notable Eligibility criteria expanded, about 19 words
    • Site details revised at 4 of 29 sites
    v8
  5. Notable Eligibility criteria expanded, about 61 words
    • Study sites: 28 to 29
    • Study description shortened, about 10 words
    v7
  6. Minor Site details revised at 4 of 28 sitesv6
  7. Notable Eligibility criteria revisedv5
  8. Notable Eligibility criteria shortened, about 23 words
    • Study sites: 26 to 28
    • Primary and study completion dates: Mar 2025 to Jun 2025
    v4
  9. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Mar 2021 to Aug 5, 2021
    • Site details revised at 26 of 26 sites
    v3
  10. Minor Secondary endpoints revised (5)v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression free survival (PFS)
Timeframe: from date to randomization to date of event, assessed up to 4 years

Secondary (5)

Objective response rate (ORR)
Incidence of treatment emergent adverse events
Time to subsequent first treatments (TTST-1)
Time to subsequent second treatments (TTST-2)
Overall Survival (OS)

Arms and interventions

Arm A : Best Supportive CareNo intervention

Observational arm (Standard of care)

Arm B : OSE2101Experimental

OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years. OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion.

Arm C : OSE2101 + PembrolizumabExperimental

OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.

Drugs: OSE2101, Pembrolizumab 25 MG/ML [Keytruda]

Sites

41 sites in 3 countries

France 32, Germany 6, Belgium 3